Aura Biosciences (NASDAQ:AURA – Get Rating) issued its quarterly earnings data on Wednesday. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.06, Yahoo Finance reports.
Aura Biosciences Stock Up 0.4 %
Shares of NASDAQ AURA opened at $10.25 on Friday. Aura Biosciences has a 1 year low of $9.43 and a 1 year high of $24.83. The stock has a fifty day moving average price of $10.55 and a two-hundred day moving average price of $12.30.
Analyst Upgrades and Downgrades
Separately, JMP Securities dropped their price target on shares of Aura Biosciences from $30.00 to $25.00 and set an “outperform” rating on the stock in a research report on Thursday.
Insider Transactions at Aura Biosciences
Institutional Trading of Aura Biosciences
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp bought a new stake in Aura Biosciences during the first quarter worth approximately $319,000. BlackRock Inc. boosted its position in shares of Aura Biosciences by 15.2% in the 1st quarter. BlackRock Inc. now owns 275,027 shares of the company’s stock valued at $6,050,000 after purchasing an additional 36,244 shares during the period. Vanguard Group Inc. increased its stake in Aura Biosciences by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 228,633 shares of the company’s stock worth $5,030,000 after purchasing an additional 2,375 shares in the last quarter. Nantahala Capital Management LLC raised its holdings in Aura Biosciences by 204.6% during the 1st quarter. Nantahala Capital Management LLC now owns 301,990 shares of the company’s stock worth $6,644,000 after buying an additional 202,844 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in Aura Biosciences by 30.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 15,379 shares of the company’s stock valued at $339,000 after buying an additional 3,557 shares in the last quarter. 55.63% of the stock is currently owned by institutional investors.
About Aura Biosciences
Aura Biosciences, Inc operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma.
- Get a free copy of the StockNews.com research report on Aura Biosciences (AURA)
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
- PacWest Bancorp May Escape a Credit Downgrade After this Happens
- Dollar General Offers Great Prices, but the Stock isn’t a Value
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.